Pluri (PLUR) Net Income towards Common Stockholders (2010 - 2025)
Pluri (PLUR) reported Net Income towards Common Stockholders of $9.0 billion for Q4 2025, up 62.24% year-over-year from $5.5 billion in Q4 2024, and up 12.66% quarter-over-quarter from $8.0 billion in Q3 2025.
Pluri (PLUR) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Pluri (PLUR) has 16 years of Net Income towards Common Stockholders data on file, last reported at $9.0 billion in Q4 2025.
- Net Income towards Common Stockholders for Q4 2025 came in at $9.0 billion, up 62.24% year-over-year; the trailing twelve-month figure through Dec 2025 was $17.0 billion (up 54.49% YoY), and the FY2025 annual result was $6.3 billion, up 20.95% from the prior year.
- Net Income towards Common Stockholders advanced to $9.0 billion in Q4 2025 per PLUR's latest filing, from $8.0 billion in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $9.0 billion in Q4 2025 and troughed at -$14.6 million in Q2 2021.
- A 5-year average of $1.4 billion and a median of -$6.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 113017.74% in 2024 and fell as far as 194.64% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$10.8 million in 2021, then surged by 36.16% to -$6.9 million in 2022, then soared by 171.18% to $4.9 million in 2023, then soared by 113017.74% to $5.5 billion in 2024, then soared by 62.24% to $9.0 billion in 2025.
- Business Quant data shows PLUR's Net Income towards Common Stockholders at $9.0 billion in Q4 2025, $8.0 billion in Q3 2025, and -$6.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Pluri | 21.39 Mn | 21.87 Mn | 86,000.00 | 9.00 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.00 Bn |
| Sep 30, 2025 | 7.99 Bn |
| Jun 30, 2025 | -6.85 Mn |
| Mar 31, 2025 | -5.61 Mn |
| Dec 31, 2024 | 5.55 Bn |
| Sep 30, 2024 | 5.45 Bn |
| Jun 30, 2024 | -6.25 Mn |
| Mar 31, 2024 | -5.75 Mn |
| Dec 31, 2023 | 4.91 Mn |
| Sep 30, 2023 | 4.96 Mn |
| Jun 30, 2023 | 6.61 Mn |
| Mar 31, 2023 | 7.76 Mn |
| Dec 31, 2022 | -6.89 Mn |
| Sep 30, 2022 | -7.12 Mn |
| Jun 30, 2022 | -8.88 Mn |
| Mar 31, 2022 | -10.48 Mn |
| Dec 31, 2021 | -10.80 Mn |
| Sep 30, 2021 | -11.44 Mn |
| Jun 30, 2021 | -14.59 Mn |
| Mar 31, 2021 | -14.23 Mn |